Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclosporine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA known ✓ | P62937 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 13/20 | 1.00 |
| ▸ | PPP3CA | Q08209 | 3/20 | 1.00 |
| ▸ | FKBP1B | P68106 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 1.00 |
| ▸ | PPIB | P23284 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclosporine SCHEMBL21170318 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23382247 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239446 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24224445 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL25083206 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239035 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192320 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23110210 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239036 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192319 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 190109 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144239-A1 | Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models | LAPIX THERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260146046-A1 | BICYCLIC FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2026-05-28 | — | — | US | claimed |
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| EP-4747378-A1 | USE OF LET-7B OR MIR-21 INHIBITORS FOR THE TREATMENT INFLAMMATORY BOWEL DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4748448-A2 | USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-27 | — | — | EP | claimed |
| EP-4746900-A1 | ACTIVE IMMUNIZATION FOR TREATING ATOPIC DERMATITIS | PRALONIR S.A.S. (UY) | 2026-05-27 | — | — | EP | claimed |
| EP-4506008-B1 | INTRAVENOUS ADMINISTRATION OF BRINCIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION | SYMBIO PHARMACEUTICALS LTD (JP) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094692-A | Rezabrutinib for the treatment of itching associated with atopic dermatitis and/or prurigo nodularis | — | 2026-05-26 | — | — | CN | claimed |
| EP-0174279-A2 | Improvements in relation to cyclosporin therapy | SANDOZ AG (CH) | 1986-03-12 | — | — | EP | claimed |
| EP-0170623-A2 | Novel pharmaceutical use of (NVA)2-cyclosporine | SANDOZ AG (CH) | 1986-02-05 | — | — | EP | claimed |
| EP-0034567-B1 | A METHOD FOR THE TOTAL SYNTHESIS OF CYCLOSPORINS AND NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1984-11-07 | — | — | EP | claimed |
| EP-0056782-B1 | NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1984-08-01 | — | — | EP | claimed |
| US-4396542-A | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production | SANDOZ LTD. (CH) | 1983-08-02 | — | — | US | claimed |
| US-4388307-A | CYCLOSPORIN WITH CARRIER OF VEGETABLE OIL, POLYALKYLENE GLYCOL TRANSESTERIFIED VEGETABLE OIL AND ETHANOL | SANDOZ LTD. (CH) | 1983-06-14 | — | — | US | claimed |
| US-4384996-A | IMMUNOSUPPRESORS AND ANTIINFLAMMATORY AGENTS | SANDOZ LTD. (CH) | 1983-05-24 | — | — | US | claimed |
| EP-0056782-A1 | Novel cyclosporins | SANDOZ AG (CH) | 1982-07-28 | — | — | EP | claimed |
| US-4288431-A | CULTURING TOLYPLOCLADIUM, CATALYTIC HYDROGENATION, REARRANGEMENT; ANTIINFLAMMATORY, IMMUNOLOGY | SANDOZ LTD. (CH) | 1981-09-08 | — | — | US | claimed |
| EP-0034567-A2 | A method for the total synthesis of cyclosporins and novel cyclosporins | SANDOZ AG (CH) | 1981-08-26 | — | — | EP | claimed |